| universal flu vaccine (M-001) / Scinai Immunotherap |
NCT01146119: Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001) |
|
|
| Completed | 2 | 200 | RoW | Multimeric-001, 500 mcg, Adjuvanted PBS, placebo, PBS and TIV 15%, PBS and TIV 50% | BiondVax Pharmaceuticals ltd. | Influenza | 05/11 | 06/11 | | |
NCT01419925: A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers |
|
|
| Completed | 2 | 120 | RoW | Two Multimeric-001 administrations followed by TIV, One administration of Multimeric-001 followed by TIV, One administration of adjuvanted M-001 followed by TIV, One administration of placebo followed by TIV | BiondVax Pharmaceuticals ltd. | Influenza, Healthy | 01/12 | 01/12 | | |
NCT02293317: Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV |
|
|
| Completed | 2 | 37 | RoW | M-001, Multimeric-001, TIV, Saline | BiondVax Pharmaceuticals ltd. | Influenza | 03/15 | 06/15 | | |
NCT00877448: A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) |
|
|
| Completed | 1/2 | 63 | RoW | Adjuvanted Multimeric-001 250 Mcg, Multimeric-001 250 Mcg, Phosphate Buffered saline, Adjuvanted PBS, Adjuvanted Multimeric-001 500 Mcg, Multimeric-001 500 Mcg, Multimeric-001 125 Mcg | BiondVax Pharmaceuticals ltd. | Healthy | 10/09 | 11/09 | | |
NCT01010737: A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers |
|
|
| Completed | 1/2 | 60 | RoW | Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Placebo, Adjuvant: Montonide isa 51 VG, Multimeric-001 500 mcg, Adjuvanted Multimeric-001 500mcg, TIV, Vaxigrip | BiondVax Pharmaceuticals ltd. | Influenza | 03/10 | 03/10 | | |
